Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 50 条

[11] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
Condorelli, Annalisa
Garibaldi, Bruno
Gagliano, Caterina
Romano, Alessandra
Del Fabro, Vittorio
Parrinello, Nunziatina Laura
Longo, Antonio
Cosentino, Sebastiano
Di Raimondo, Francesco
Conticello, Concetta
ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
[12] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
Stocker, Nicolas
HEMATOLOGIE, 2020, 26 (02): : 99 - 100
[13] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
Becnel, Melody R.
Lee, Hans C.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[14] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
Condorelli, Annalisa
Garibaldi, Bruno
Gagliano, Caterina
Romano, Alessandra
Del Fabro, Vittorio
Parrinello, Nunziatina Laura
Longo, Antonio
Cosentino, Sebastiano
Di Raimondo, Francesco
Conticello, Concetta
ACTA HAEMATOLOGICA, 2021,
[15] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
Callander, Natalie S.
Richardson, Paul G.
Hus, Marek
Ribrag, Vincent
Lopez, Joaquin Martinez
Kim, Kihyun
Lee, Jae Hoon
Dimopoulos, Meletis
Schjesvold, Fredrik
Facon, Thierry
Jo, Jae-Cheol
Min, Chang-Ki
Mielnik, Michal
Cheng, Shinta
Smith, L. Mary
Breitbach, Caroline J.
Brawley, Chris
Sembhi, Harjeet
LaMacchia, John
Hakim, Shawn
Kremer, Brandon E.
Grosicki, Sebastian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
[16] DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma
Sunami, Kazutaka
Iida, Shinsuke
Tsukada, Nobuhiro
Fujii, Taku
Kato, Hitomi
Fukushima, Ryuichi
Wakabayashi, Satoshi
Nakano, Hirofumi
Roy-Ghanta, Sumita
Kremer, Brandon E.
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 174 - 186
[17] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3
Leypoldt, L.
Callander, N. S.
Richardson, P. G.
Hus, M.
Ribrag, V.
Lopez, J. M.
Kim, K.
Lee, J. H.
Dimopoulos, M. A.
Schjesvold, F.
Facon, T.
Jo, J. -C.
Min, C. -K.
Mielnik, M.
Cheng, S.
Smith, L. M.
Breitbach, C. J.
Brawley, C.
Sembhi, H.
LaMacchia, J.
Grosicki, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 177
[18] Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
Iida, Shinsuke
Sunami, Kazutaka
Mishima, Yuko
Fujii, Taku
Kato, Hitomi
Terao, Takumi
Matsuzawa, Yuki
Matsubara, Mari
Crossman, Timothy
Kremer, Brandon E.
Gupta, Ira
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (05) : 596 - 608
[19] Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
Shinsuke Iida
Kazutaka Sunami
Yuko Mishima
Taku Fujii
Hitomi Kato
Takumi Terao
Yuki Matsuzawa
Mari Matsubara
Timothy Crossman
Brandon E. Kremer
Ira Gupta
International Journal of Hematology, 2023, 118 : 596 - 608
[20] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
Suvannasankha, Attaya
Bahlis, Nizar J.
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Rocafiguera, Albert Oriol
Voorhees, Peter M.
Alonso, Aranzazu Alonso
Callander, Natalie Scott
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Patel, Nashita
Williams, Danae
Jewell, Roxanne C.
Zhou, Xiangdong
Gupta, Ira V.
Nooka, Ajay K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →